What is BillionToOne, Inc. 's accrued clinical expenses?

BillionToOne, Inc. (BLLN) reported accrued clinical expenses of $224K in Q1 2026.

What does accrued clinical expenses mean?

This captures unpaid obligations related to clinical trials, laboratory testing, or medical research activities. It provides visibility into the near-term cash requirements necessary to sustain the company's clinical development and diagnostic validation pipeline.

BillionToOne, Inc. BLLN Accrued clinical expenses

Accrued clinical expenses at other companies

Ionis PharmaceuticalsIONS

$53.33M-21.1%

Schering-PloughSGP

$2.18M+70.2%

Nuvalent, Inc.NUVL

$58.92M+20.6%

Praxis Precision Medicines, Inc.PRAX

$17.65M+13.5%

Madrigal Pharmaceuticals, Inc.MDGL

$34.33M+87.9%

Spyre Therapeutics, Inc.SYRE

$29.16M+34.8%

Other financials

Income statement

See full

Revenue$108.4M+83.8%

Gross profit$79.1M+108%

Operating income$17.8M+870%

Net income$18.0M+551%

EPS (diluted)$0.34+187%

Balance sheet

See full

Cash & equivalents$537.5M+181%

Total debt$144.2M—

Total equity$505.6M+300%

Total assets$700.7M—

Cash flow

See full

Operating cash flow$15.4M+488%

CapEx$4.5M+90.5%

Free cash flow$11.0M+3,842%

Valuation

See full

Market cap$4.84B—

Profitability

See full

Gross margin70.4%—

Operating margin-96.9%—

Net margin8.4%—

FCF margin-83.4%—

Returns & leverage

See full

Debt / equity0.3×—

Current ratio10.9×—

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept blln:AccruedClinicalExpensesCurrent.

The official record: BillionToOne, Inc. ’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's accrued clinical expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BillionToOne, Inc. 's accrued clinical expenses?: BillionToOne, Inc. (BLLN) reported accrued clinical expenses of $224K in Q1 2026.
What does accrued clinical expenses mean?: This captures unpaid obligations related to clinical trials, laboratory testing, or medical research activities. It provides visibility into the near-term cash requirements necessary to sustain the company's clinical development and diagnostic validation pipeline.